Abiogen acquires EffRx to fortify bone disease portfolio
Pharmaceutical Technology
MAY 30, 2023
The company has developed three bisphosphonates, clodronate, alendronate and Nerixia (neridronate), for the treatment of bone pathologies such as osteoarthritis. The company developed and launched Binosto (alendronate sodium) as the first and only buffered solution for osteoporosis. Alkindi is one of EffRx’s three marketed drugs.
Let's personalize your content